

Journal of Nephrology

Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues

Azar Baradaran^{1,*}

¹Department of Clinical Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.

ARTICLE INFO

Article type:
Editorial

Article history:

Received: 12 May 2012

Revised: 18 May 2012

Accepted: 29 May 2012

Published online:

1 October 2012

DOI: 10.5812/nephrologypathol.8107

Keywords:

Lipoprotein(a)

Renal failure

Diabetic nephropathy

Implication for health policy/practice/research/medical education:

Studies suggested that serum lipoprotein (a) [Lp (a)] concentration may take part in aggravation of diabetic nephropathy. In contrast, some investigators believe that, the association of Lp (a) with diabetic nephropathy is likely to be weak or nonexistent. It seems that serum Lp (a) can be considered as a promising predictive factor for the diagnosis of earlier diabetic nephropathy, However, prospective studies are needed to determine its role.

Please cite this paper as: Baradaran A. Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues. J Nephrology. 2012; 1(3): 126-129.

DOI: 10.5812/nephrologypathol.8107

Lipoprotein (a) [Lp (a)] is an important cardiovascular risk factor in the general population (1-6). However, data on the risks conferred by Lp(a) in patients with diabetes mellitus specially in diabetic nephropathy are scarce and controversial and it is not well known, whether, in diabetic state, Lipoprotein (a) affects nephropathy. While various studies have shown that Lp(a) can be associated with diabetic complications, its association with diabetic nephropathy is still unclear (7). While atherosclerosis is a major complication associated with diabetes mellitus(DM), various studies has been focused

on elucidating the possible role of Lp(a) in this disease, when epidemiological studies have implicated high levels of plasma lipoprotein(a) with increased risk for atherosclerotic cardiovascular disease(8). However, controversy exists as to whether lipoprotein(a) directly influences the nephropathy of diabetes(9). It was previously shown that, Lp(a) levels can be considered an independent risk factor for the development of atherosclerosis in type 2 diabetes(T2D) (10). It was assumed that, glycation of proteins, ie, nonenzymatic glycosylation resulting from the high plasma glucose levels found in diabetes,

*Corresponding author: Dr. Azar Baradaran, Department of Clinical Pathology, Isfahan University of Medical Sciences, Isfahan, Iran. Telephone: +98 311 6691565, Fax: +98 311 6684510, Email: azarbaradaran@med.mui.ac.ir

is thought to be one of the factors contributing to the severity of this disease. Indeed glycation produces modest increases in the degradation rate of Lp(a). However, glycation does not appear to enhance the atherogenic potential of unmodified Lp(a) significantly (8). In contrast, it was shown that Lp(a) was associated inversely with risk of type 2 diabetes independently of risk factors, in contrast to prior findings of positive associations of Lp(a) with cardiovascular risks (11). Similarly, the effect of Lp(a) on the risk factors of cardiovascular disease among diabetic patients might be different from that in the general population (11,12). Diabetes status may even attenuate the relation between Lp(a) and cardiovascular risk (12). Studied showed that high Lp(a) level and diabetes mellitus are independent markers of a greater extent of intracranial large-artery occlusive disease. These findings support the role of Lp(a) in intracranial stenotic atherogenesis and might be useful for the selection of high-risk patients (13). Also, available data showed that high Lp(a) level seems to be an independent risk factor for myocardial infarction in this T2DM cohort (14). It was also found that T2D had significant effects on Lp(a) concentrations (15,16). To evaluate the association of Lp(a) and hypertension (HTN) as a part of diabetic nephropathy aggravation, Nasri conducted a study on T2D patients (17), who were under treatments of oral hypoglycemic agents or insulin injections (17). He studied 122 patients, 82 females and 40 males with a mean age of 63 ± 10 years and duration of Diabetes mellitus and HTN of 7.4 ± 5.8 and 3.2 ± 4.6 years, respectively. The mean systolic and diastolic blood pressure (BP) were 138 ± 23 mmHg and 83 ± 12 mmHg, respectively. The mean serum Lp(a) was 22.2 ± 24.7 mg/dL (median: 18.3 mg/dL), and serum Lp(a) levels > 30 mg/dL was found in 29

(23.8%) patients. There were significant positive correlations duration of DM and duration of hypertension, with serum Lp(a). He suggested that kidney function is an independent determinant of Lp(a) and HTN in diabetic patients (17). In addition, they concluded that Lp(a) may have important implications for the increased susceptibility to vascular disease in diabetic patients (17). Whether Lp(a) is an independent risk factor for deteriorating renal function in type 2 diabetic patients with nephropathy? In a prospective study in type 2 diabetic patients with overt proteinuria, Song et al. demonstrated that Lp(a) is an independent risk factor for the progression of diabetic nephropathy in T2D with overt proteinuria, and is an independent predictor of the progression of diabetic nephropathy (18). The mechanism by which elevated Lp(a) levels might adversely affect the progression of diabetic nephropathy is not well known. It may be due to the atherogenic effect of Lp(a) which leads to renal ischemia because of increased atherosclerotic renal artery stenosis (18). In addition to vascular injury, Lp(a) might be implicated in glomerular injury (19). Lp(a) and oxidized Lp(a) have been shown to induce activation of reactive oxygen metabolites in isolated rat glomeruli (18,19). While Nakhjavani et al. (20) showed the significant difference of Lp(a) between males and females with a female preponderance, in another study conducted by Onuma et al., a possible role for Lp(a) as an independent risk factor for diabetic retinopathy in male patients with T2D was suggested (21). They showed that, in T2D patients, Lp(a) levels are elevated compared to non-diabetic subjects, and that higher Lp(a) levels are associated with higher prevalence of coronary artery disease and of retinopathy (22). Similarly, in a study on 76 insulin dependent diabetic patients, Kapelrud et al. found that serum

concentration of Lp(a) lipoprotein are twice as high in insulin dependent diabetic patients with microalbuminuria as in those without microalbuminuria. They concluded that increased concentrations of Lp(a) lipoprotein might partly explain the increased morbidity and mortality of cardiovascular disease observed among patients with diabetic nephropathy (22). Likewise, in a study conducted in China on a group of diabetic patients, the relationship between lipoprotein(a) level and progression of early diabetic nephropathy and also the significance of lowering of serum Lp(a) in preventing the progression of early diabetic nephropathy, was studied. Study was conducted on a group of non-diabetic controls and T2D including 90 patients without DN and 96 with microalbuminuria. Ninety-six patients with early diabetic nephropathy were randomly divided into control group and treatment group which was treated with 40 microgram of oral fluvastatin every night in addition to routine therapy. They found that, Lp(a) was significantly decreased in treatment group, accompanied by decrease in urinary albumin and serum creatinine. They concluded that, Increased serum Lp(a) may be associated with the progression of early diabetic nephropathy. Lowering serum Lp(a) can ameliorate microalbuminuria and improve renal function in patients with early diabetic nephropathy (23). Also, in a similar study in china, lowering serum Lp(a) by the same drug can ameliorate microalbuminuria and postpone the occurrence of renal failure in T2D (24). In conclusion, studies have suggested that serum Lp(a) concentration may take part in aggravation of diabetic nephropathy. In contrast, some investigators, believe that, the association of Lp(a) with diabetic nephropathy is likely weak or nonexistent. It seems that serum Lp(a) can be considered as a promising predictive factor for

the diagnosis of earlier nephropathy. However, more prospective studies are needed to determine such a role.

Acknowledgments

None declared.

Financial Disclosure

The author declared no competing interests.

Funding/Support

None declared.

References

1. Nasri H, Baradaran A. Association of serum lipoprotein(a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral arteries in kidney transplanted patients. *Transplant Proc.* 2004;36(9):2683-6.
2. Baradaran A, Nasri H, Ganji F. Association of serum lipoprotein(a) with intima-media thickness as a target-organ damage in essential hypertensive patients. *Iran Heart J.* 2004;5:55-63. http://www.sid.ir/en/VEWSSID/J_pdf/86820040304.pdf
3. Baradaran A, Nasri H, Ganji F. Close relationship of serum lipoprotein (a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral artery in end-stage renal failure patients undergoing hemodialysis. *Timok Med J (Journal of Regional Section of Serbian Medical Association in Zajecar).* 2004;29(1):8-13. <http://www.tmg.org.rs/v290102e.htm>
4. Nasri H, Baradaran A. Association of Early Atherosclerotic Vascular Changes with Serum Lipoprotein (a) in Pre-dialysis Chronic Renal Failure and Maintenance Hemodialysis Patients. *Saudi J Kidney Dis Transpl.* 2005;16(2):154-60.
5. Baradaran A, Nasri H. Association of serum lipoprotein(a) with left ventricular hypertrophy in hemodialysis patients. *Indian J Nephrol.* 2004;14:41-5. <http://medind.nic.in/iav/t04/i2/iavt04i2p41.pdf>
6. Nasri H, Baradaran HR. Lipids in association with serum magnesium in diabetes mellitus patients. *Bratisl Lek Listy.* 2008;109(7):302-6.
7. Zambon S, Baldo-Enzi G, Baiocchi M, Nosadini R, Manzato E, Crepaldi G. Lipoprotein(a) levels in type II diabetic patients are not influenced by metabolic control or by microalbuminuria. *Diabetes Care.* 1994;17(12):1548-9.

8. Makino K , Furbee JW, Jr . , Scanu AM, Fless GM . Effect of glycation on the properties of lipoprotein(a). *Arterioscler Thromb Vasc Biol.* 1995;15(3):385-91.
9. Suk Danik J, Rifai N, Buring JE, Ridker PM . Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. *JAMA.* 2006;296(11):1363-70.
10. Martinez-Triguero ML , Salvador A , Samper MJ , Almela M , Vega L , Mora A , et al. Lipoprotein (a) and other risk factors in patients with non-insulin-dependent diabetes mellitus. *Coron Artery Dis.* 1994;5(9):755-60.
11. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG , Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. *Clin Chem.* 2010;56(8):1252-60.
12. Qi Q, Workalemahu T, Zhang C, Hu FB, Qi L . Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. *Eur Heart J.* 2012;33(3):325-34.
13. Arenillas JF, Molina CA, Chacon P, Rovira A, Montaner J, Coscojuela P , et al. High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. *Neurology.* 2004;63(1):27-32.
14. Velho G, Erlich D, Turpin E, Neel D, Cohen D, Froguel P, et al. Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM. *Diabetes Care.* 1993;16(5):742-7.
15. Rainwater DL, MacCluer JW, Stern MP, VandeBerg JL, Haffner SM. Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size. *Diabetes.* 1994;43(7):942-6.
16. Gazzaruso C, Coppola A, Montalcini T, Baffero E, Garzaniti A, Pelissero G, et al. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. *Endocrine.* 2012;41(1):89-95.
17. Nasri H. Association of serum lipoprotein (a) with hypertension in diabetic patients. *Saudi J Kidney Dis Transpl.* 2008;19(3):420-7.
18. Song KH, Ko SH, Kim HW, Ahn YB, Lee JM, Son HS, et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. *Diabetes Care.* 2005;28(7):1718-23.
19. Greiber S, Kreusel M, Pavenstadt H, Schollmeyer P, Wanner C . Lipoprotein(a) induces glomerular superoxide anion production. *Nephrol Dial Transplant.* 1997;12(7):1330-5.
20. Nakhjavani M, Morteza A, Esteghamati A, Khalilzadeh O, Zandieh A, Safari R . Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes. *Lipids.* 46(4):349-56.
21. Onuma T, Kikuchi T, Shimura M, Tsutsui M, Matsui J, Boku A , et al. Lipoprotein(a) as an independent risk factor for diabetic retinopathy in male patients in non-insulin-dependent diabetes mellitus. *Tohoku J Exp Med.* 1994;173(2):209-16.
22. Kapelrud H, Bangstad HJ, Dahl-Jorgensen K, Berg K, Hanssen KF. Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. *BMJ.* 1991;303(6804):675-8.
23. LIN H, WU H, KUANG M. Correlation Between Lipoprotein (a) Level and Progression of Early Diabetic Nephropathy. *Chinese Journal of Integrated Traditional and Western Nephrology.* 2004;8
24. ZHOU H, LI S, ZHANG L. Observation of relationship between different level of serum lipoprotein (a) and renal function in Type II diabetics. *Journal of Dali University.* 2007;4